NeoGenomics Valuation
| NEO Stock | USD 9.82 0.30 3.15% |
At this time, the firm appears to be undervalued. NeoGenomics secures a last-minute Real Value of $12.57 per share. The latest price of the firm is $9.82. Our model forecasts the value of NeoGenomics from analyzing the firm fundamentals such as Current Valuation of 1.53 B, return on equity of -0.0854, and Profit Margin of (0.12) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that NeoGenomics' price fluctuation is slightly risky at this time. Calculation of the real value of NeoGenomics is based on 3 months time horizon. Increasing NeoGenomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeoGenomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeoGenomics Stock. However, NeoGenomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.82 | Real 12.57 | Hype 9.21 | Naive 11.08 |
The intrinsic value of NeoGenomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NeoGenomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NeoGenomics helps investors to forecast how NeoGenomics stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeoGenomics more accurately as focusing exclusively on NeoGenomics' fundamentals will not take into account other important factors: NeoGenomics Total Value Analysis
NeoGenomics is now forecasted to have company total value of 1.53 B with market capitalization of 1.22 B, debt of 605.33 M, and cash on hands of 465.95 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the NeoGenomics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.53 B | 1.22 B | 605.33 M | 465.95 M |
NeoGenomics Investor Information
About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeoGenomics has Price/Earnings (P/E) ratio of 272.37. The entity recorded a loss per share of 0.62. The firm had not issued any dividends in recent years. NeoGenomics had 1:100 split on the 16th of April 2003. Based on the key indicators related to NeoGenomics' liquidity, profitability, solvency, and operating efficiency, NeoGenomics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.NeoGenomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NeoGenomics has an asset utilization ratio of 40.33 percent. This suggests that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that NeoGenomics is more efficient with each dollar of assets it utilizes for everyday operations.NeoGenomics Ownership Allocation
NeoGenomics maintains a total of 128.46 Million outstanding shares. The majority of NeoGenomics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NeoGenomics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NeoGenomics. Please pay attention to any change in the institutional holdings of NeoGenomics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.NeoGenomics Profitability Analysis
The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 290.1 M.About NeoGenomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of NeoGenomics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NeoGenomics based exclusively on its fundamental and basic technical indicators. By analyzing NeoGenomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of NeoGenomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of NeoGenomics. We calculate exposure to NeoGenomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NeoGenomics's related companies.NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people.
NeoGenomics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 126.7 M | |
| Quarterly Earnings Growth Y O Y | 1.306 | |
| Forward Price Earnings | 222.2222 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.